Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan

PHASE2RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Environmental Enteric Dysfunction (EED)Stunting
Interventions
DRUG

Oral Vancomycin

Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation

DRUG

VE818

VE818 is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women.

DRUG

Placebo

Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)

Trial Locations (1)

71000

RECRUITING

Mother and Child Health Research and Training Center, AKU, Matiari

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

collaborator

University of Zambia

OTHER

collaborator

Institut Pasteur de Dakar

OTHER

lead

Aga Khan University

OTHER

NCT07207434 - Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan | Biotech Hunter | Biotech Hunter